SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-22-006729
Filing Date
2022-04-29
Accepted
2022-04-29 16:27:39
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tals_2022_defa14a.htm DEFA14A 20488
2 GRAPHIC img117147532_0.jpg GRAPHIC 91925
3 GRAPHIC img117147532_1.jpg GRAPHIC 59206
  Complete submission text file 0000950170-22-006729.txt   229902
Mailing Address 300 E. MARKET ST. SUITE 350 LOUISVILLE KY 40202
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40384 | Film No.: 22876043
SIC: 2836 Biological Products, (No Diagnostic Substances)